Characteristics
|
circRHOBTB3 expression level
|
miR-600 expression level
|
NACC1 expression level
|
---|
High
|
Low
|
P-value
|
High
|
Low
|
P-value
|
High
|
Low
|
P-value
|
---|
Total cases
|
55
|
55
| |
55
|
55
| |
55
|
55
| |
Gender
|
Male
|
38
|
37
|
0.838
|
39
|
36
|
0.539
|
38
|
37
|
0.838
|
Female
|
17
|
18
| |
16
|
19
| |
17
|
18
| |
Age (year)
|
< 60
|
41
|
32
|
0.069
|
32
|
41
|
0.069
|
40
|
33
|
0.158
|
≥ 60
|
14
|
23
| |
23
|
14
| |
15
|
22
| |
Serum CA19–9(U/mL)
|
CA19–9 < 39
|
5
|
14
|
0.076
|
11
|
8
|
0.545
|
6
|
13
|
0.209
|
39 ≤ CA19–9 < 1000
|
38
|
31
| |
35
|
34
| |
36
|
33
| |
CA19–9 ≥ 1000
|
12
|
10
| |
9
|
13
| |
13
|
9
| |
Location
|
Head
|
36
|
37
|
0.84
|
36
|
28
|
0.738
|
37
|
37
|
1
|
Body/tail
|
19
|
18
| |
19
|
17
| |
18
|
18
| |
Diameter (cm)
|
≤ 4
|
36
|
48
|
0.007**
|
47
|
37
|
0.025*
|
32
|
51
|
< 0.0001***
|
> 4
|
19
|
7
| |
8
|
18
| |
23
|
4
| |
Differentiation
|
Poor/moderate
|
36
|
33
|
0.554
|
33
|
36
|
0.554
|
33
|
35
|
0.695
|
Well
|
19
|
22
| |
22
|
19
| |
22
|
20
| |
Vascular invasion
|
Present
|
44
|
33
|
0.022*
|
30
|
43
|
0.009**
|
40
|
35
|
0.306
|
Absent
|
11
|
22
| |
25
|
12
| |
15
|
20
| |
Nerve invasion
|
Present
|
52
|
47
|
0.112
|
49
|
49
|
1
|
49
|
50
|
0.751
|
Absent
|
3
|
8
| |
6
|
6
| |
6
|
5
| |
T stage
|
T1/T2
|
24
|
36
|
0.022*
|
36
|
24
|
0.022*
|
26
|
33
|
0.181
|
T3/T4
|
31
|
19
| |
19
|
31
| |
29
|
22
| |
N stage
|
N0
|
21
|
26
|
0.335
|
26
|
21
|
0.335
|
26
|
21
|
0.335
|
N1/N2
|
34
|
29
| |
29
|
34
| |
29
|
34
| |
M stage
|
M0
|
54
|
54
|
1
|
54
|
54
|
1
|
55
|
53
|
0.154
|
M1
|
1
|
1
| |
1
|
1
| |
0
|
2
| |
Clinical stage
|
I-IIa
|
18
|
20
|
0.688
|
25
|
13
|
0.016*
|
19
|
19
|
1
|
IIb-IV
|
37
|
35
| |
30
|
42
| |
36
|
36
| |
Postoperative Recurrence or liver metastasis
|
Present
|
31
|
31
|
1
|
33
|
31
|
0.699
|
33
|
30
|
0.563
|
Absent
|
24
|
24
| |
22
|
24
| |
22
|
25
| |
- All data are presented as the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001